EUVIMEDSkopri EUVIMED
Open access · CC BY-NC-ND 4.0

CD19 / BCMA ‐Targeted Chimeric Antigen Receptor‐T Cell Therapy for Anti‐ HLA Antibody Sensitisation in Patients With Acute Leukaemia: A Pilot Clinical Study

Haiqiong Zheng, Houli Zhao iD, Xinyi Zhu, Jingjing Feng, Guoqing Wei, Shi Han, Simao Huang, Jiazhen Cui, Shan Fu, Mingming Zhang, Yanlei Zhang, Jimin Shi and 4 more

HLA · 2026-05 · 107 (5)

DOI: 10.1111/tan.70701 ↗

At a glance

Journal article in HLA, published online on 2026-05-15. Written by Haiqiong Zheng and 15 co-authors. Institution: Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, School of Medicine, Zhejiang University, Hangzhou, China. Major MEDLINE topics: HLA Antigens, Antigens, CD19, Receptors, Chimeric Antigen, Leukemia, Myeloid, Acute. 28 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: National Natural Science Foundation of China, National Key Research and Development Program of China, Zhejiang Province's Vanguard Geese Leading Plan Project.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Antibodies targeting foreign HLA molecules can be detrimental in transplantation. Nonetheless, existing desensitisation methods for anti‐HLA antibodies frequently prove insufficient. We conducted a single‐arm pilot study to evaluate CD19/B cell maturation antigen (BCMA) chimeric antigen receptor T (CAR‐T) cell therapy for desensitising anti‐HLA antibodies prior to transplantation. Seven patients diagnosed with acute leukaemia participated in the study, comprising four individuals with acute myeloid leukaemia (AML) and three with acute B lymphoblastic leukaemia (B‐ALL). Among them, one patient was treated with BCMA CAR‐T cells, while six received CD19 CAR‐T cells. No instances of neurotoxicity or severe cytokine release syndrome (grade ≥ 3) were noted. CAR‐T cell expansion was observed in six patients (86%), with the exception of patient 3. Among the seven patients with pre‐infusion anti‐HLA‐I antibodies, five (71%) showed a decrease in mean fluorescence intensity (MFI), including three (43%) who experienced a reduction greater than 75%. Among the six patients confirmed to exhibit CAR‐T cell expansion in vivo, three presented with donor‐specific anti‐HLA antibodies (DSAs) prior to CAR‐T cell infusion. The median MFI level of DSA declined from 15797.8 (7750.3–21106.0) to 3831.1 (523.3–13197.0) ( p < 0.001) in the three patients studied. Two patients with decreased DSA levels after CD19 CAR‐T cell infusion underwent combined desensitisation before haematopoietic stem cell transplantation. This pilot study illustrates the potential safety and efficacy of CD19 and BCMA CAR‐T cells in desensitising anti‐HLA antibodies in patients with AML or B‐ALL. However, only one patient received BCMA CAR‐T cells in our cohort, so further research with an expanded sample size is essential for comprehensively evaluating the safety and efficacy of CD19/BCMA CAR‐T cell therapy for anti‐HLA antibody sensitisation.

Subjects

MeSH terms (MEDLINE)

HLA AntigensAntigens, CD19Receptors, Chimeric AntigenLeukemia, Myeloid, AcuteB-Cell Maturation AntigenImmunotherapy, AdoptiveT-LymphocytesPrecursor Cell Lymphoblastic Leukemia-LymphomaDesensitization, ImmunologicHumansPilot ProjectsFemaleAdultMaleMiddle AgedAdolescentYoung Adult

Author keywords

BCMACAR‐TCD19DSAanti‐HLA antibodyleukaemia

Substances

HLA AntigensAntigens, CD19Receptors, Chimeric AntigenB-Cell Maturation AntigenCD19 molecule, human

Authors and institutions

  • Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, School of Medicine, Zhejiang University, Hangzhou, China.
  • Institute of Hematology, Zhejiang University, Hangzhou, China.
  • Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China.
  • Shanghai YaKe Biotechnology Ltd., Shanghai, China.
  • Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai, China.

ORCID profiles: Houli Zhao, Yi Luo, Yongxian Hu, He Huang

Funding

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Zhejiang Province's Vanguard Geese Leading Plan Project
  • Sanming Project of Medicine in Shenzen Municipality
  • Postdoctoral Fellowship Program of the CPSF

Cite

APA

Zheng, H., Zhao, H., Zhu, X., Feng, J., Wei, G., Han, S., Huang, S., Cui, J., Fu, S., Zhang, M., Zhang, Y., Shi, J., Luo, Y., Chang, A. H., Hu, Y., & Huang, H. (2026). CD19 / BCMA ‐Targeted Chimeric Antigen Receptor‐T Cell Therapy for Anti‐ HLA Antibody Sensitisation in Patients With Acute Leukaemia: A Pilot Clinical Study. HLA, 107(5). https://doi.org/10.1111/tan.70701

Vancouver

Zheng H, Zhao H, Zhu X, Feng J, Wei G, Han S, et al. CD19 / BCMA ‐Targeted Chimeric Antigen Receptor‐T Cell Therapy for Anti‐ HLA Antibody Sensitisation in Patients With Acute Leukaemia: A Pilot Clinical Study. HLA. 2026;107(5). doi:10.1111/tan.70701

BibTeX
@article{Zheng2026,
  author = {Zheng, Haiqiong and Zhao, Houli and Zhu, Xinyi and Feng, Jingjing and Wei, Guoqing and Han, Shi and Huang, Simao and Cui, Jiazhen and Fu, Shan and Zhang, Mingming and Zhang, Yanlei and Shi, Jimin and Luo, Yi and Chang, Alex H and Hu, Yongxian and Huang, He},
  title = {CD19 / BCMA ‐Targeted Chimeric Antigen Receptor‐T Cell Therapy for Anti‐ HLA Antibody Sensitisation in Patients With Acute Leukaemia: A Pilot Clinical Study},
  journal = {HLA},
  year = {2026},
  volume = {107},
  number = {5},
  doi = {10.1111/tan.70701}
}
Start for free →